Pod Save America Hosts Call on Democrats to Cut All Israel Military Aid, No Longer Accept AIPAC Funding
Jews, Israelis Targeted in Austria Amid Surge in Antisemitic Incidents; Local Jewish Community Calls for Action
‘All of Our Strength’: Over 1,000 Pro-Israel Activists Gather in DC for Solidarity Conference
‘Devastated’: Wesley LePatner, Killed in Manhattan Mass Shooting, Was a Jewish Communal, Philanthropic Leader
Sen. Angus King Vows to No Longer Vote for Israel Military Aid Until Gaza Conditions Improve
Europe Won’t Pressure Israel to ‘Commit Suicide’ Amid Gaza Backlash, Palestinian State Push, Says Israeli FM
Israel’s National Soccer Coach Attacked in Athens Before Soccer Fans Chant ‘F–K Israel, Free Palestine’ at Match
New York Judge Sentences Neo-Nazi to 5 Years for Livestreaming Bomb Threats Against Jewish Hospitals
US Pressures Lebanon to Issue Cabinet Decision to Disarm Hezbollah Before Talks Continue
UK Plans to Recognize Palestinian State in September Unless Israel Meets Conditions, Starmer Says
U.S. FDA Approves Israeli Company’s Lung Cancer Scanning System; Shares Surge 18% on TASE
Error: Contact form not found.
by Joshua Levitt
BioView's DUET-3 scanning station. Photo: BV.
Shares of Israeli biotech firm BioView surged 18.7% to NIS 3.45 on Wednesday after the U.S. Food and Drug Administration approved its Duet scanning system for the detection of mutations in lung cancer patients, Israel’s Globes business daily reported.
In a statement, Dr. Alan Schwebel, BioView President and CEO said, “We are pleased to receive FDA approval for the new application. This, along with our distribution agreement with Abbot Molecular and the broad range of applications will allow us to continue to penetrate the pathology lab market and to position BioView as a world leader.”
For cancer testing, BioView’s products offer a one-stop solution for the preparation of samples, scanning slides, analyzing results and preparing reports.
According to the U.S. National Cancer Institute, lung cancer is the cancer with the highest mortality rate around the world. In the U.S., there are more than 250,000 new diagnoses, and 160,000 deaths, each year.
